NYSE$SYK
Stryker Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Stryker's Q3 2021 financial results reflected solid performance amidst COVID-19 resurgence.
Stryker reported a solid third quarter in 2021 with net sales increasing by 11.3% compared to 2020 and 16.0% compared to 2019, reaching $4.2 billion. The company saw growth in MedSurg and NeuroTech businesses, although U.S. implant related businesses were impacted by deferred procedures due to a resurgence of COVID-19. Reported EPS decreased by 30.1% to $1.14, while adjusted EPS increased by 2.8% to $2.20.
- Reported net sales increased 11.3% from 2020 and 16.0% from 2019, reaching $4.2 billion.
- Organic net sales increased 4.5% from 2020 and 8.4% from 2019.
- Reported EPS decreased 30.1% to $1.14.
- Adjusted EPS increased 2.8% to $2.20.
Headline financials
Revenue & EPS history
Stryker · Revenue · Quarterly
$4.16B
Revenue by segment
Stryker · $1.53B total across 1 segment · Q3 2021
- Orthopaedics$1.53B+16.1%100.0%
Forward guidance
Stryker expects 2021 organic net sales growth to be in the range of 7% to 8% from 2019. Adjusted net earnings per diluted share are expected to be in the range of $9.08 to $9.15, including the full year impact of the acquisition of Wright Medical. EPS will be positively impacted by approximately $0.05 to $0.10 for the full year if foreign currency exchange rates hold near current levels.
Tailwinds
- Expected 2021 organic net sales growth in the range of 7% to 8% from 2019.
- Adjusted net earnings per diluted share expected to be in the range of $9.08 to $9.15.
- Includes the full year impact of the acquisition of Wright Medical.
- EPS positively impacted by approximately $0.05 to $0.10 for the full year if foreign currency exchange rates hold near current levels.
- Monitoring and evaluating the impact of the global response to the COVID-19 pandemic on operations and financial results.
Headwinds
- Volatility experienced as a result of COVID.
- Labor and staffing environment in healthcare potentially hindering an accelerated recovery.
- Unable to predict with reasonable certainty the impact and timing of restructuring-related and other charges.
- Unable to predict with reasonable certainty acquisition-related expenses and fair value adjustments to inventory.
- Unable to predict with reasonable certainty the outcome of certain regulatory, legal and tax matters.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.7%
Avg return
30 days after
58%
42 / 73 earnings
Positive
+11.8%
Q4 2022
Best reaction
-6.3%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.4% | -7.2% | -3.0% | |
| Q4 2025 | +2.6% | +1.8% | +9.4% | |
| Q3 2025 | -3.0% | -3.1% | +0.6% | |
| Q2 2025 | +0.0% | -0.4% | +3.6% | |
| Q1 2025 | +1.0% | +2.7% | +2.3% | |
| Q4 2024 | -2.2% | -2.2% | -2.8% | |
| Q3 2024 | +2.1% | +3.1% | +9.0% | |
| Q2 2024 | -1.7% | -0.5% | +7.4% | |
| Q1 2024 | -3.2% | -3.1% | +0.5% | |
| Q4 2023 | +6.7% | +8.8% | +11.0% | |
| Q3 2023 | +1.5% | +1.1% | +9.5% | |
| Q2 2023 | +3.3% | +2.8% | +3.6% | |
| Q1 2023 | -1.9% | -5.0% | -8.0% | |
| Q4 2022 | +11.8% | +13.5% | +5.0% | |
| Q3 2022 | -4.0% | -8.0% | +2.0% | |
| Q2 2022 | +5.1% | +6.6% | +7.5% | |
| Q1 2022 | -3.2% | -4.5% | -5.1% | |
| Q4 2021 | +0.1% | +0.1% | +7.1% | |
| Q3 2021 | -0.9% | +1.5% | -9.3% | |
| Q2 2021 | +2.0% | +2.8% | +2.9% | |
| Q1 2021 | -2.1% | -1.0% | -4.1% | |
| Q4 2020 | -3.4% | -4.8% | +2.0% | |
| Q3 2020 | -1.4% | +1.6% | +13.6% | |
| Q2 2020 | -4.0% | -6.0% | -1.6% | |
| Q1 2020 | -6.3% | -2.5% | +1.6% | |
| Q4 2019 | -1.8% | -1.8% | -9.2% | |
| Q3 2019 | +1.6% | -0.4% | -4.1% | |
| Q2 2019 | +0.4% | +0.0% | +0.2% | |
| Q1 2019 | +1.6% | +3.4% | +1.3% | |
| Q4 2018 | +10.7% | +9.5% | +16.4% | |
| Q3 2018 | -1.7% | -0.7% | +1.0% | |
| Q2 2018 | -2.7% | -3.2% | -3.0% | |
| Q1 2018 | +3.2% | +2.2% | +5.1% | |
| Q4 2017 | -2.6% | -3.9% | -5.6% | |
| Q3 2017 | +6.4% | +3.1% | +3.0% | |
| Q2 2017 | +1.4% | +1.5% | -4.0% | |
| Q1 2017 | +1.3% | +1.4% | +4.8% | |
| Q4 2016 | -0.2% | +3.3% | +3.6% | |
| Q3 2016 | +4.0% | +4.5% | +2.7% | |
| Q2 2016 | -4.4% | -4.8% | -7.0% | |
| Q1 2016 | -0.4% | — | — | |
| Q4 2015 | +4.4% | — | — | |
| Q3 2015 | -5.4% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q4 2014 | +0.2% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2014 | -0.2% | — | — | |
| Q1 2014 | -1.1% | — | — | |
| Q4 2013 | -1.0% | — | — | |
| Q3 2013 | +2.7% | — | — | |
| Q2 2013 | +2.2% | — | — | |
| Q1 2013 | +1.1% | — | — | |
| Q4 2012 | +2.8% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | -2.9% | — | — | |
| Q1 2012 | +2.2% | — | — | |
| Q4 2011 | -0.0% | — | — | |
| Q3 2011 | -2.9% | — | — | |
| Q2 2011 | -0.3% | — | — | |
| Q1 2011 | +0.2% | — | — | |
| Q4 2010 | +1.9% | — | — | |
| Q3 2010 | +2.3% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2009 | -1.1% | — | — | |
| Q1 2010 | +0.2% | — | — | |
| Q4 2009 | +1.9% | — | — | |
| Q4 2007 | +1.9% | — | — | |
| Q3 2008 | +2.9% | — | — | |
| Q3 2009 | +2.9% | — | — | |
| Q2 2009 | +5.1% | — | — | |
| Q2 2008 | +5.1% | — | — | |
| Q4 2008 | +5.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro